Nine days to go until expiration of period during 907 Ph2 trial at which time Curis hopefully will have sufficiently positive data to make its pitch to FDA for conversion to pivotal trial.
9:05 Small Molecule Antagonists of Immune Checkpoint Pathways Pottayil_SasikumarPottayil G. Sasikumar, Ph.D., Associate Research Director, Medicinal Chemistry, Aurigene Discovery Technologies Ltd. Immune checkpoint antibodies have revolutionized cancer therapy because of their impressive clinical activity. However, they suffer from the shortcomings including the failure to show response in a majority of patients, need to administer by intravenous injection and immune-related adverse events. We are developing small molecule immune checkpoint antagonists that do not exhibit these limitations. CA-170, a candidate from this approach dually targeting PD-L1 and VISTA is now undergoing clinical trials.
Wow! New Corporate presentation in the web site (June). We can read in the page 8:
Study Ongoing - Based on results, potential for discussion with FDA for accelerated registration path - Enrolling in 25 centers in the US and Europe - RESPONSES HAVE BEEN OBSERVED - Preliminary study read-out in Q3 2017
I think these are nice words... "read between lines..."
David Tuck speaking on June 13th; last time he spoke regarding Ph1 370 trial in November, stock soared, so if Ali has nothing much to say tomorrow, maybe Tuck will at the World Preclinical Congress. I am getting desperate for a catalyst.
10:50 Development, Discovery and Details of the Oral Small Molecule Checkpoint Inhibitors, CA170 and CA327 David Tuck, M.D., CMO, Curis, Inc. CA-170 is a first-in-class, orally-available, small molecule antagonist of the immune checkpoints PD-L1 and VISTA. CA-170 is currently undergoing investigation in a Phase I clinical trial in patients with advanced solid tumors and lymphoma. CA-327 is a first-in-class, orally-available, small molecule antagonist of the immune checkpoints PD-L1 and TIM3. CA-327 is currently undergoing IND-enabling studies, and the company expects to file an IND and initiate clinical testing of CA-327 in 2017.
Explain me ! Explain me ! Friday + 0,18 cents. Monday -0,18 cents. ASCO expectations? No my God. Welcome to the Casino and good luck.
Monster MicroCaps Research Alert to CRIS shareholders. Clean energy Technologies (CETY) is under 2 pennies with a market cap of under $4 million and just announced it is expanding operations and marketing by opening Sales & Service Center in Europe to serve the current 65 HRS (Heat Recovery Systems) installations and to expand sales in Europe.
CETY technology was purchased from General Electric in 2015 and is attractive to huge unmet markets that can achieve over $250 million annual sales within the next 2 to 3 years. Demand for conversion of wasted heat to electrical energy in large applications is very large and unmet!
Each CETY HRS (Heat Recovery System) sells for about $300,000.
Clean Energy Technologies, Inc. Establishes CETY Europe Sales and Service Center
COSTA MESA, Calif., June 1, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (OTC: CETY) announced today that it has established a new CETY Europe Sales and Service Center in Silea (Treviso), Italy. ...
CRIS stock in 6 months? 👍👎
CRIS appears to suggest upside opportunity. have you guys heard of awe.some.stocks. i started receiving their allerts and so far i am happy.
It is not easy the life of CRIS. Nice jump yesterday at close with good volume. Nice jump today at open with nice volume again. But it seems today some fund are adjusting his position considering today it is the May close. 1M shares traded at 1.69-1.81 range... and we are there, in the minimun.
buying AXSM at $4 is like buying JAZZ at $1 a few years ago now trading at $151 (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
Will ASCO presentation be good news? Will stock price rise? Hope news is encouraging.
Yes, it is old news, but impressive (all the information at 03/31/2017... tons of shares bought by Institutions):
FMR LLC 03/31/2017 15,131,961 393,582 2.67 25,270 BLACKROCK INC. 03/31/2017 9,181,022 9,173,474 121,535.16 15,332 MILLENNIUM MANAGEMENT LLC 03/31/2017 2,272,318 1,078,340 90.32 3,795 VANGUARD GROUP INC 03/31/2017 4,827,625 304,268 6.73 8,062 CORMORANT ASSET MANAGEMENT, LLC 03/31/2017 2,000,000 (410,900) (17.04) 3,340 STATE STREET CORP 03/31/2017 1,681,620 17,640 1.06 2,808 POLAR CAPITAL LLP 03/31/2017 1,641,176 121,050 7.96 2,741 NORTHERN TRUST CORP 03/31/2017 1,285,369 29,758 2.37 2,147 ADAGE CAPITAL PARTNERS GP, L.L.C. 03/31/2017 1,040,000 5,000 .48 1,737 GEODE CAPITAL MANAGEMENT, LLC 03/31/2017 918,592 70,139 8.27 1,534 ROYAL BANK OF CANADA 03/31/2017 912,296 44,290 5.10 1,524 D. E. SHAW & CO., INC. 03/31/2017 772,320 66,250 9.38 1,290 POINT72 ASSET MANAGEMENT, L.P. 03/31/2017 500,400 500,400 New 836 PERCEPTIVE ADVISORS LLC 03/31/2017 500,000 500,000 New 835 AMERIPRISE FINANCIAL INC 03/31/2017 476,773 (27,674) (5.49) 796 TIAA CREF INVESTMENT MANAGEMENT LLC 03/31/2017 470,027 (76,584) (14.01) 785 DEUTSCHE BANK AG\ 03/31/2017 407,642 (130,434) (24.24) 681
Like Otis, I am sitting on the dock of the bay watching the Curis ship roll in and then roll away. Right now Curis lost at sea, but after listening again to March 9th earnings conference call, regarding 907 Curis ship will start rolling back in starting with Jefferies conference in early June. If 907 interim data is positive to the point that Curis seeks meeting with FDA, then stock should jump back to 3. If Cris indicates it will not disclose data until after getting FDA go ahead, and earliest news is announcement that FDA has given CRIS green light for conversion to pivotal, then a buyer now will have doubled his or her money by end of summer. If CA-170 news is positive, then the price triples.
Sinking into the abyss, NASDAQ is smoking higher and this POS is efin down every efin day!
You are pitiful Ali, you waste of a load!
This POS stock doesn't move for anything when the NASDAQ is moving higher but, always seems to sink when the market is selling off.
Ali and this management are the worst POS ever!
See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio. BioLargo recent 10Q states: • Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days • Woundcare market is over $6 Billion with high growth rate • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost • Sales could commence late 2017 • Sales and or licensing agreement/s could be very significant and fast • Company is now commercializing several other disruptive products in large markets
Looks like the next time the 13-F's are released, there will probably be a lot less investors holding CRIS
McNab is probably dumping every last share now that hes not chairman anymore. This is the worst management team in biotech. $1 billion in losses and these incompetent a-holes are still destroying shareholders daily. Corrupt corrupt corrupt